Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion

With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.

By | January 27, 2017

FLICKRJohnson & Johnson will buy Actelion, a Swiss biotech firm that develops drugs for rare diseases, in a $30 billion deal according to Reuters. Under the terms of the agreement, Actelion will be spun off into a new company that will focus on drug discovery.

“We believe this transaction offers compelling value to both Johnson & Johnson and Actelion shareholders,” said Alex Gorsky, CEO of Johnson & Johnson, in a press release. Gorsky added that he hopes the deal will position the US healthcare giant to “continue Actelion’s legacy of innovation” and develop “cutting-edge new therapies”.

The deal, which Reuters reported as the biggest European pharmaceutical takeover in 13 years, also allows Johnson & Johnson to option “ACT-132577,” an Actelion drug that treats pulmonary hypertension and is now entering Phase 2 clinical trials. 

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  2. 2017 Top 10 Innovations
    Features 2017 Top 10 Innovations

    From single-cell analysis to whole-genome sequencing, this year’s best new products shine on many levels.

  3. Search for Life on the Red Planet
  4. Two Dozen House Republicans Do an About-Face on Tuition Tax
FreeShip